Open AccessIN VITRO INCORPORATION OF 3 H‐THYMIDINE, 3 H‐URIDINE, 3 H‐LEUCINE AND 3 H‐MELPHALAN BY PLASMACYTOMA PLASMA CELLS
Author(s) -
Ponti G. B.,
Eridani S.,
Astaldi G.,
Giangrande A.
Publication year - 1969
Publication title -
cell proliferation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.647
H-Index - 74
eISSN - 1365-2184
pISSN - 0960-7722
DOI - 10.1111/j.1365-2184.1969.tb01002.x
Subject(s) - thymidine , uridine , melphalan , leucine , plasmacytoma , in vitro , labelling , tritium , bone marrow , chemistry , phenylalanine , microbiology and biotechnology , biochemistry , biology , multiple myeloma , immunology , rna , amino acid , physics , nuclear physics , gene
Bone marrow plasma cells from fifteen cases of multiple myeloma, immunologically typed, were incubated with different tritiated compounds. The labelling index with tritiated thymidine is generally low, while the mean grain count is fairly normal in the active cells. The labelling index of 3 H‐uridine and 3 H‐leucine was very high, while the mean grain count per cell lies within the normal range. The results obtained with 3 H‐phenylalanine‐mustard (melphalan), which is a drug used in the treatment of the plasmacytoma, show also incorporation values roughly comparable to those of 3 H‐leucine. The present data seem to support the clinical use of melphalan as a compound that is actively incorporated into the plasma cells of plasmacytoma although inhibition of protein synthesis due to specific binding to protein was not demonstrated.